Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease

Identifier	20220215_nanos_sciplatform3_01
Title	Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease
Creator	Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas
Affiliation	(PSS) University of Colorado, Aurora, CO; (SS) (RH) Horizon Therapeutics plc, Deerfield, IL; (RSD) Cedars Sinai Medical Center Los Angeles; Shanghai International Medical Center
Subject	Neuro-ophthalmology & Systemic Disease (eg. MS, MG, Thyroid); Graves' Disease
Description	Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non- responders could receive a course of teprotumumab in the OPTIC-X study. This analysis examined sustainability of response over the follow-up periods from the phase 2, OPTIC and OPTIC-X studies, including the recently proposed EUGOGO composite outcome.
Date	2022-02
Language	eng
Format	video/mp4
Type	Image/MovingImage
Source	2022 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of	NANOS Annual Meeting 2022: Scientific Platform III
Collection	Neuro-Ophthalmology Virtual Education Library: NANOS Annual Meeting Collection: https://novel.utah.edu/collection/nanos-annual-meeting-collection/
Publisher	North American Neuro-Ophthalmology Society
Holding Institution	Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management	Copyright 2022. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK	ark:/87278/s6a7xdfv
Setname	ehsl_novel_nam
ID	2187015
Reference URL	https://collections.lib.utah.edu/ark:/87278/s6a7xdfv